vTv Therapeutics (VTVT) Net Income towards Common Stockholders (2014 - 2026)

vTv Therapeutics has disclosed Net Income towards Common Stockholders across 13 years of filings, most recently posting $24.1 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $24.1 million, up 573.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (up 112.05% YoY), and the FY2025 annual result was -$27.0 million, down 46.11% from the prior year.
• Net Income towards Common Stockholders came in at $24.1 million for Q1 2026 at vTv Therapeutics, up from -$7.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $24.1 million in Q1 2026 to a low of -$8.7 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$4.9 million (2024), against an average of -$3.6 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 418.26% in 2022 and soared 573.96% in 2026, its largest moves.
• vTv Therapeutics' Net Income towards Common Stockholders stood at -$4.7 million in 2022, then advanced by 26.7% to -$3.5 million in 2023, then slipped by 4.49% to -$3.6 million in 2024, then slumped by 96.42% to -$7.1 million in 2025, then jumped by 438.11% to $24.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $24.1 million (Q1 2026), -$7.1 million (Q4 2025), and -$8.7 million (Q3 2025), per Business Quant data.